News

Qtern is a fixed-dose combination of saxagliptin and dapagliflozin, two oral blood glucose lowering medicines, indicated in adults aged 18 years and older with type 2 diabetes. It intends to

The reference product is approved in the European Union for use in moderate to severe rheumatoid arthritis (RA), ankylosing spondylitis, moderate to severe plaque psoriasis, active and progressive

Tiziana bought the biobank as well as other key assets from Cagliari-based biobanking and genomics research firm Shardna for a total of €258,000. The acquisition allows Tiziana to

The LIBERTY study will evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH). Despite multiple approved vasodilator therapies, PAH

This approval will initiate the first store brand launch of an equivalent product to Zegerid OTC capsules. This product will be packaged and marketed as a store brand or

The high demand for site-specific labeling technologies and potential for deal-making in the field of antibody-drug conjugates (ADC) that has emerged during APC's recent business development activities, particularly

The Company intends to use the net proceeds from this capital increase as follows:      • To initiate and progress the Phase 3 Imeglimin program in Japan

The projected FDA’s action date is 11 November, while the EMA's centralized review process is underway. The data supporting both applications were generated in the phase 3 Checkmate-141

The objectives of the trial are to demonstrate: 1. IntelGenx oral film product will provide therapeutically effective blood levels of montelukast, and; 2. montelukast when delivered using IntelGenx